PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-224315.95%
Both yoy net incomes decline, with TRAW at -615.12%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
418.75%
D&A growth well above TRAW's 16.00%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
2984.50%
SBC growth while TRAW is negative at -94.27%. John Neff would see competitor possibly controlling share issuance more tightly.
29070.41%
Slight usage while TRAW is negative at -175.50%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5571250.00%
A yoy AP increase while TRAW is negative at -184.48%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
12125.42%
Some yoy usage while TRAW is negative at -159.09%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
753.88%
Some yoy increase while TRAW is negative at -99.99%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-298628.16%
Both yoy CFO lines are negative, with TRAW at -166.64%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-260.15%
Both yoy lines negative, with TRAW at -18.40%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-260.15%
Both yoy lines negative, with TRAW at -18.40%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
